Radiolabeled prostate specific membrane antigen inhibitors

Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: The invention also provides pharmaceutical compositions of a complex of a radionuclide and a Formula I compound or a Formula II compound and methods of using the radionuclide complex of a Formula I compound or a...

Full description

Saved in:
Bibliographic Details
Main Authors LU, GENLIANG, JOYAL, JOHN L, BABICH, JOHN W, ZIMMERMAN, CRAIG
Format Patent
LanguageEnglish
Published 06.03.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: The invention also provides pharmaceutical compositions of a complex of a radionuclide and a Formula I compound or a Formula II compound and methods of using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.
Bibliography:Application Number: AU20120294639